Cognition Therapeutics inc (CGTX) - News Archive

Alzheimer s disease (AD) stands as one of the most pressing public health challenges of our era, with trajectories marked by increasing prevalence rates among aging populations. In response to this crisis, Cognition The...

Cognition Therapeutics, Inc. is making notable strides in the field of neurodegenerative disorders with its lead investigational product, zervimesine (CT1812). As a clinical-stage company focused on drugs for conditions...

Cognition Therapeutics Inc., a biotechnology company specializing in therapies for neurodegenerative diseases, has recently announced a significant registered direct offering of common stock valued at $30 million. This...

Targeting Dry AMD: Cognition Therapeutics Unveils Promising Preclinical Data on Zervimesine for Retinal Cell HealthIn a significant advancement in the ongoing battle against neurodegenerative disorders, Cognition Therap...

Cognition Therapeutics Granted Extension for Compliance with Nasdaq Listing Requirements Amid Struggles in Share PricePURCHASE, N.Y. March 12, 2025 Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biotech c...

The field of neurodegenerative research is often marked by incremental progress, punctuated by breakthroughs that redefine our understanding and treatment of complex disorders. Cognition Therapeutics, a notable player i...

In an ambitious stride towards combating dementia, Cognition Therapeutics, Inc. has announced the culmination of all participant visits in the eagerly anticipated Phase 2 SHIMMER study, which investigates the efficacy o...

Alzheimer s disease (AD) remains a numbing specter over millions worldwide, with traditional therapeutic approaches often falling short in addressing its insidious cognitive decline. Recent studies by Cognition Therapeu...

As September marks Lewy Body Dementia Awareness Month, Cognition Therapeutics Inc. is taking significant steps to elevate public understanding of this often-overlooked neurodegenerative disorder, while simultaneously ad...

Promising EEG Findings from Cognition Therapeutics Phase 2 SEQUEL Study for Alzheimer s Disease Treatment Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage biopharmaceutical company focused on developing dru...

Cognition Therapeutics, a biotechnology company dedicated to developing innovative treatments for neurodegenerative diseases, recently announced the results of its Phase 2 SHINE trial for CT1812, a drug formulated to ad...

In a recent episode of Conversations, Cognition Therapeutics sheds light on the critical role of protecting synapses from amyloid toxicity in Alzheimer s disease. This clinical stage company, known as Cognition (NASDAQ:...

Cognition Therapeutics, a leading biopharmaceutical company, recently completed the enrollment process for its Phase 2 SHIMMER (Study to Highlight Imaging in Mild-to-Moderate Dementia with Lewy Bodies and - Top-line Res...

In an exciting development, Cognition Therapeutics, a clinical-stage company specializing in neurodegenerative disorder treatments, has successfully closed its underwritten public offering of common stock. With an impre...

Cognition Therapeutics Plans Public Offering of Common Stock to Advance Neurodegenerative Disorder TreatmentsPURCHASE, N. Y., March 11, 2024 - Cognition Therapeutics, a clinical stage biopharmaceutical company focused o...

Cognition Therapeutics Presents Groundbreaking Analyses Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer s Disease Studies at AD/PD 2024 ConferenceCognition Therapeutics, a clinical stage biot...

In a recent letter to shareholders, the CEO of Cognition Therapeutics, a leading clinical-stage biopharmaceutical company, shed light on the company s upcoming milestones, particularly the anticipated release of topline...